Cargando…

Development of CMV-CD19 bi-specific CAR T cells with post-infusion in vivo boost using an anti-CMV vaccine

Adoptive transfer of in vitro expanded, chimeric antigen receptor (CAR)-redirected CD19-specific T cells can induce dramatic disease regression in patients with leukemia and lymphomas. However, the full potential of this emerging modality is hampered in some cancer settings by a significant rate of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Xiuli, Diamond, Don J., Forman, Stephen J., Nakamura, Ryotaro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Singapore 2021
Materias:	Progress in Hematology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8475363/ https://www.ncbi.nlm.nih.gov/pubmed/34561840 http://dx.doi.org/10.1007/s12185-021-03215-6

Ejemplares similares

Large-scale manufacturing and characterization of CMV-CD19CAR T cells
por: Wang, Xiuli, et al.
Publicado: (2022)

Efforts to maximize the potential of CAR-T therapy for cancer, from T-bodies to CAR-immune cells
por: Fujiwara, Hiroshi
Publicado: (2021)

Pre-clinical data supporting immunotherapy for HIV using CMV-HIV-specific CAR T cells with CMV vaccine
por: Guan, Min, et al.
Publicado: (2022)

Engineering the next generation of CAR-NK immunotherapies
por: Biederstädt, Alexander, et al.
Publicado: (2021)

Exciting Times for Cytomegalovirus (CMV) Vaccine Development: Navigating the Pathways toward the Goal of Protecting Infants against Congenital CMV Infection
por: Schleiss, Mark R., et al.
Publicado: (2020)

Recombinant luciferase-expressing human cytomegalovirus (CMV) for evaluation of CMV inhibitors
por: He, Ran, et al.
Publicado: (2011)

Ex vivo manufacturing of platelets: beyond the first-in-human clinical trial using autologous iPSC-platelets
por: Chen, Si Jing, et al.
Publicado: (2022)

Cytopenias following anti-CD19 chimeric antigen receptor (CAR) T cell therapy: a systematic analysis for contributing factors
por: Xia, Yuan, et al.
Publicado: (2022)

Blinatumomab as salvage therapy in patients with relapsed/refractory B-ALL who have failed/progressed after anti-CD19-CAR T therapy
por: Qi, Yao, et al.
Publicado: (2023)

Correlation of Cytomegalovirus (CMV) Disease Severity and Mortality With CMV Viral Burden in CMV-Seropositive Donor and CMV-Seronegative Solid Organ Transplant Recipients
por: McBride, Jacqueline M, et al.
Publicado: (2019)

Effect of ageing on CMV-specific CD8 T cells from CMV seropositive healthy donors
por: Pita-Lopez, María Luisa, et al.
Publicado: (2009)

The Immunology of Posttransplant CMV Infection: Potential Effect of CMV Immunoglobulins on Distinct Components of the Immune Response to CMV
por: Carbone, Javier
Publicado: (2016)

CMV Immunoglobulins for the Treatment of CMV Infections in Thoracic Transplant Recipients
por: Schulz, Uwe, et al.
Publicado: (2016)

Predictors of CMV Infection in CMV-Seropositive Kidney Transplant Recipients: Impact of Pretransplant CMV-Specific Humoral Immunity
por: Kirisri, Similan, et al.
Publicado: (2021)

Association of CMV-Specific T Cell-Mediated Immunity with CMV DNAemia and Development of CMV Disease in HIV-1–Infected Individuals
por: Aichelburg, Maximilian C., et al.
Publicado: (2015)

Stimulatory Effect of CMV Immunoglobulin on Innate Immunity and on the Immunogenicity of CMV Antigens
por: Deml, Ludwig, et al.
Publicado: (2021)

CMV in the gut: a critical review of CMV detection in the immunocompetent host with colitis
por: Goodman, A. L., et al.
Publicado: (2014)

2121. The Impact of Donor CMV Serostatus on Outcomes of CMV Infections in the Era of Letermovir
por: Aramburo, Oscar Morado, et al.
Publicado: (2022)

Levels of CMV Specific CD4 T Cells Are Dynamic and Correlate with CMV Viremia after Allogeneic Stem Cell Transplantation
por: Widmann, Thomas, et al.
Publicado: (2008)

Association of CMV genomic mutations with symptomatic infection and hearing loss in congenital CMV infection
por: Dobbins, G. Clement, et al.
Publicado: (2019)

RhCMV serostatus and vaccine adjuvant impact immunogenicity of RhCMV/SIV vaccines
por: Chang, W. L. William, et al.
Publicado: (2020)

The hallmarks of CMV-specific CD8 T-cell differentiation
por: van den Berg, Sara P. H., et al.
Publicado: (2019)

Iron chelation therapy in the myelodysplastic syndromes and aplastic anemia: a review of experience in South Korea
por: Lee, Jong Wook
Publicado: (2008)

Japanese epidemiological survey with consensus statement on Japanese guidelines for treatment of iron overload in bone marrow failure syndromes
por: Suzuki, Takahiro, et al.
Publicado: (2008)

Body iron metabolism and pathophysiology of iron overload
por: Kohgo, Yutaka, et al.
Publicado: (2008)

Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload
por: Gattermann, Norbert
Publicado: (2008)

Diversity of disseminated intravascular coagulation and selection of appropriate treatments
por: Asakura, Hidesaku
Publicado: (2020)

COVID-19-associated coagulopathy and disseminated intravascular coagulation
por: Asakura, Hidesaku, et al.
Publicado: (2020)

Recent advances in the research and management of sepsis-associated DIC
por: Iba, Toshiaki, et al.
Publicado: (2021)

FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation
por: Biavasco, Francesca, et al.
Publicado: (2022)

Multiple myeloma with high-risk cytogenetics and its treatment approach
por: Hanamura, Ichiro
Publicado: (2022)

Unique features of vaccine-induced immune thrombotic thrombocytopenia; a new anti-platelet factor 4 antibody-mediated disorder
por: Venier, Laura M., et al.
Publicado: (2022)

The role of epigenetics in T-cell lymphoma
por: Yamagishi, Makoto
Publicado: (2022)

Immune dysregulation in multiple myeloma: the current and future role of cell-based immunotherapy
por: Russell, Brian M., et al.
Publicado: (2023)

Progress in pathophysiological understanding and treatment of thrombocytopenia
por: Kashiwagi, Hirokazu
Publicado: (2023)

CMV-Responsive CD4 T Cells Have a Stable Cytotoxic Phenotype Over the First Year Post-Transplant in Patients Without Evidence of CMV Viremia
por: Higdon, Lauren E., et al.
Publicado: (2022)

604 Risk Factors for Cytomegalovirus (CMV) Reactivation in CMV-seropositive Liver Transplant Patients
por: Bruminhent, Jackrapong, et al.
Publicado: (2014)

THE PREVALENCE OF CYTOMEGALOVIRUS (CMV) VIRURIA AMONG HOSPITALIZED CHILDREN AND THE RISK OF CMV ACQUISITION BY NURSES
por: Adler, Stuart P, et al.
Publicado: (1984)

cmv1-Mediated Resistance to CMV in Melon Can Be Overcome by Mixed Infections with Potyviruses
por: Giordano, Andrea, et al.
Publicado: (2023)

Correction to: Association of CMV genomic mutations with symptomatic infection and hearing loss in congenital CMV infection
por: Dobbins, G. Clement, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5jtl5h66e95u64757tk2jfevlm